{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:16:15Z","timestamp":1791350175838,"version":"4.3.1"},"reference-count":38,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T00:00:00Z","timestamp":1682467200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Euro J of Neurology"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and purpose<\/jats:title>\n                    <jats:p>The response pattern to monoclonal antibodies against calcitonin gene\u2010related peptide (anti\u2010CGRP MAbs) shown in migraine prevention clinical trials is not always reproducible at an individual level. This study was undertaken to describe patterns of start and consistency of the response to anti\u2010CGRP MAbs during the first 6\u2009months of treatment and the association with baseline clinical characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a prospective clinical cohort observational study. We included migraine patients treated with erenumab or galcanezumab evaluated at baseline and after 3 and 6\u2009months (M3, M6) of treatment. The response was categorized according to reduction in monthly headache days (MHD): Sustained\u2010response (SustainedR, \u226550% at M3 and M6), Short\u2010Response (ShortR, M3 \u226550% and M6 &lt;50%), Late\u2010Response (LateR, M3 &lt;50% and M6 \u226550%), Limited\u2010Response (LimitedR, 25%\u201350% at M3 and M6), and No\u2010Response (NoR, &lt;25% at M3 and M6). Response patterns were compared at baseline and with outcome variables at M3 and M6.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 357 patients with a headache frequency of 21.0 (interquartile range\u2009=\u200916.0\u201328.0) MHD, and 84.0% (300\/357) were chronic migraine. The distribution according to response pattern was 37.0% (110\/297) SustainedR, 16.8% (50\/297) LateR, 10.4% (31\/297) ShortR, 22.6% (67\/297) LimitedR, and 13.1% NoR (39\/297). The SustainedR and LateR groups showed statistically significant anxiety and depression score reduction at M3 and M6 compared to the other groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Initial response to anti\u2010CGRP MAbs is not consistent in all patients. Persistence of anxiety and depression might be associated with lower response rates at M6.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ene.15816","type":"journal-article","created":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T00:39:10Z","timestamp":1681173550000},"page":"1937-1944","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Patterns of response to\n                    <scp>anti\u2010calcitonin gene\u2010related peptide<\/scp>\n                    monoclonal antibodies during first 6 months of treatment in resistant migraine patients: Impact on outcome"],"prefix":"10.1111","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2856-4134","authenticated-orcid":false,"given":"Marta","family":"Torres\u2010Ferrus","sequence":"first","affiliation":[{"name":"Headache Unit, Neurology Department Hospital Universitari Vall d'Hebron  Barcelona Spain"},{"name":"Headache and Neurological Pain Research Group Departament de Medicina Vall d'Hebron Research Institute Universitat Aut\u00f2noma de Barcelona  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3042-2007","authenticated-orcid":false,"given":"Victor J.","family":"Gallardo","sequence":"additional","affiliation":[{"name":"Headache and Neurological Pain Research Group Departament de Medicina Vall d'Hebron Research Institute Universitat Aut\u00f2noma de Barcelona  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5296-9401","authenticated-orcid":false,"given":"Alicia","family":"Alpuente","sequence":"additional","affiliation":[{"name":"Headache Unit, Neurology Department Hospital Universitari Vall d'Hebron  Barcelona Spain"},{"name":"Headache and Neurological Pain Research Group Departament de Medicina Vall d'Hebron Research Institute Universitat Aut\u00f2noma de Barcelona  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5525-0267","authenticated-orcid":false,"given":"Edoardo","family":"Caronna","sequence":"additional","affiliation":[{"name":"Headache Unit, Neurology Department Hospital Universitari Vall d'Hebron  Barcelona Spain"},{"name":"Headache and Neurological Pain Research Group Departament de Medicina Vall d'Hebron Research Institute Universitat Aut\u00f2noma de Barcelona  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5286-7605","authenticated-orcid":false,"given":"Eulalia","family":"Gin\u00e9\u2010Cipr\u00e9s","sequence":"additional","affiliation":[{"name":"Headache Unit, Neurology Department Hospital Universitari Vall d'Hebron  Barcelona Spain"},{"name":"Headache and Neurological Pain Research Group Departament de Medicina Vall d'Hebron Research Institute Universitat Aut\u00f2noma de Barcelona  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0796-4702","authenticated-orcid":false,"given":"Patricia","family":"Pozo\u2010Rosich","sequence":"additional","affiliation":[{"name":"Headache Unit, Neurology Department Hospital Universitari Vall d'Hebron  Barcelona Spain"},{"name":"Headache and Neurological Pain Research Group Departament de Medicina Vall d'Hebron Research Institute Universitat Aut\u00f2noma de Barcelona  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,4,26]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705848"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709038"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.1212"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.4853"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006640"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009169"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418779543"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418759786"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420905132"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30083-2"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0923-6"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14007"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13691"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-018-1193-2"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01279-7"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13654"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01127-0"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10523-8"},{"key":"e_1_2_9_20_1","first-page":"4","article-title":"Anti\u2010CGRP monoclonal antibodies in chronic migraine with medication overuse: real\u2010life effectiveness and predictors of response at 6 months","volume":"1","author":"Caronna E","year":"2021","journal-title":"J Headache Pain"},{"key":"e_1_2_9_21_1","first-page":"1","article-title":"Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)","volume":"1","author":"Vernieri F","year":"2021","journal-title":"J Headache Pain"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14194"},{"key":"e_1_2_9_23_1","first-page":"1","volume-title":"Informe de Posicionamiento terap\u00e9utico Erenumab","author":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios","year":"2019"},{"key":"e_1_2_9_24_1","first-page":"1","volume-title":"Informe de Posicionamiento Galcanezumab","author":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios","year":"2019"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01130-5"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.suppl_1.S20"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1037\/0022-006X.56.6.893"},{"key":"e_1_2_9_28_1","volume-title":"Manual for the Beck Depression Inventory\u2010II (BDI\u2010II)","author":"Beck A","year":"1996"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v045.i03"},{"key":"e_1_2_9_30_1","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2013"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-320242"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14193"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15075"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15236"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15197"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01333-4"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26472"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-017-0787-1"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01431-x"}],"container-title":["European Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.15816","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T16:49:43Z","timestamp":1692463783000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ene.15816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,26]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.1111\/ene.15816"],"URL":"https:\/\/doi.org\/10.1111\/ene.15816","archive":["Portico"],"relation":{},"ISSN":["1351-5101","1468-1331"],"issn-type":[{"value":"1351-5101","type":"print"},{"value":"1468-1331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,26]]},"assertion":[{"value":"2022-10-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}